Welcome to our dedicated page for Catalyst Pharmaceuticals SEC filings (Ticker: CPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) SEC filings page on Stock Titan provides structured access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a commercial-stage biopharmaceutical company focused on rare and difficult-to-treat diseases, Catalyst uses its filings to report on financial performance, material events, capital allocation decisions, and developments affecting its product portfolio, including FIRDAPSE, AGAMREE, and FYCOMPA.
Investors can review current reports on Form 8-K, where Catalyst discloses events such as quarterly financial results, authorization of share repurchase programs, patent litigation settlements related to FIRDAPSE, changes to clinical practice guidelines referencing Lambert-Eaton myasthenic syndrome and amifampridine, and updates to its Board of Directors. These filings often incorporate press releases as exhibits, providing additional context on how specific events may influence the company’s operations and CPRX stock.
In addition to event-driven 8-Ks, users can access periodic reports like Forms 10-Q and 10-K, which contain detailed discussions of product revenue, research and development spending, selling and administrative costs, and other aspects of Catalyst’s business. For a biopharmaceutical issuer, these reports are key resources for understanding revenue contributions from individual products, the status of rare disease programs, and the company’s approach to intellectual property and litigation.
Stock Titan enhances these documents with AI-powered summaries that highlight the main points of lengthy filings, helping users quickly identify items such as revenue trends, material agreements, or litigation outcomes. The platform also surfaces insider transaction reports on Form 4 when available, giving additional visibility into trading activity by officers and directors. With real-time updates from EDGAR and simplified explanations of complex regulatory documents, this CPRX filings page supports efficient, in-depth analysis of Catalyst Pharmaceuticals’ regulatory record.
Daniel J. Curran, a director of Catalyst Pharmaceuticals (CPRX), reports no direct common stock ownership and holds options to acquire 40,000 shares at an exercise price of $21.12. The options vest in three annual tranches beginning August 1, 2026 and expire on August 1, 2032, creating multi-year equity alignment with the company.
Period: Quarterly report for Catalyst Pharmaceuticals, Inc. (CPRX) for the six months ended June 30, 2025.
Key financials: Total revenues $287,984 thousand; product revenue $287,940 thousand; operating income $129,665 thousand; net income $108,845 thousand; diluted EPS $0.86; cash and cash equivalents $652,800 thousand; total assets $971,915 thousand as of June 30, 2025.
Product mix and material items: FIRDAPSE $168,576 thousand, FYCOMPA $69,959 thousand, AGAMREE $49,405 thousand for the six months ended June 30, 2025. Customer A accounted for 75.3% of net product revenue for the six months ended June 30, 2025. Company states it has sufficient funds for at least 12 months and completed a public offering on January 9, 2024 raising net proceeds of approximately $140.7 million.